Hemodialysis Patient Data on Immune and Mitochondrial Health from a 20-Person Trial

Supplementary file 1 from a study investigating the effects of combined hemoperfusion and high-flux hemodialysis on 20 maintenance hemodialysis patients. The data likely contains pre- and post-intervention measurements of T lymphocyte subsets, mitochondrial membrane potential, protein-bound uremic toxins, and patient-reported outcomes. The dataset was authored by Qi Zhong and last updated on 2026-05-21.

Use Cases

• Analyzing changes in T lymphocyte subsets (CD3+, CD4+, CD8+) based on repeated measurements from a clinical trial.
• Investigating correlations between protein-bound uremic toxin levels (indoxyl sulphate, p-cresyl sulphate) and patient-reported outcomes like sleep quality and pruritus.
• Studying the relationship between mitochondrial membrane potential in T cells and clinical improvements in hemodialysis patients.
• Comparing pre- and post-treatment levels of serum phosphorus and parathyroid hormone based on the described intervention.

Strengths

• Data originates from a prospective, self-controlled clinical trial with a defined protocol.
• Includes multiple biomarker types: immune cells, mitochondrial health, toxins, and patient-reported quality of life scores.
• Measurements were taken at specific time points (before and after 12 intervention sessions).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study design is a single-arm, observational trial, which the authors note is hypothesis-generating.

Provenance

Source

figshare, author Qi Zhong.

Collection Method

Data collected from a single-center, prospective, self-controlled clinical trial.

Time Range

Temporal coverage of the clinical trial is not specified.

Freshness

Last updated 2026-05-21 04:19:23; freshness should be verified.

Geography

Spatial coverage is not specified; the trial was single-center.